Markets
Intellia Therapeutics Stock Jumps 4%, Adding $59 Million In Market Value
The gene-editing developer's latest quarter brought a 48% revenue decline and a $127.5 million net loss.
Intellia Therapeutics (NTLA) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Markets
The gene-editing developer's latest quarter brought a 48% revenue decline and a $127.5 million net loss.
Markets
Coverage and center readiness would determine whether the launch plan's envisioned wait of three to six months between potential approval and first treatments and revenue holds.
SEC Filings
An illustrative launch timetable puts first treatments and revenue three to six months after potential approval.
SEC Filings
Intellia is building commercial infrastructure while losing money, with an FDA target decision date of March 10, 2027.